Sana Biotechnology, Inc. - SANA STOCK NEWS

Sana Biotechnology highlighted a new publication in Nature Biotechnology revealing promising preclinical data on pluripotent stem cell-derived human glial progenitor cells (hGPCs) as a treatment for Huntington’s disease and other neurodegenerative conditions. The study demonstrated that healthy hGPCs effectively replaced diseased glial cells in the brains of chimeric mice. This proof-of-concept supports the development of SC379, Sana’s hGPC product candidate, for potential clinical applications in various neurological disorders. Sana aims to begin clinical testing of SC379 by 2025. The study showed significant replacement of diseased cells with healthy cells over a period of 54 to 72 weeks, indicating strong therapeutic potential.

Sana Biotechnology reported its first quarter 2024 financial results and business updates, highlighting ongoing clinical trials in seven indications and a goal to treat 40-60 patients in four trials. The company completed financing of $189.8 million and has a cash position of $311.1 million with expected 2024 operating cash burn below $200 million. Sana is focused on understanding its hypoimmune platform and its impact on prevalent diseases.

Sana Biotechnology, Inc. (NASDAQ: SANA) will be presenting at three investor conferences in May and June 2024. The presentations will include a business overview and updates, with webcasts accessible on their Investor Relations page. Sana will present at the Citizens JMP Securities Life Sciences Conference on May 13, the BofA Securities 2024 Healthcare Conference on May 14, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10. The replay of each presentation will be available for 30 days after the conference.

Sana Biotechnology, Inc. (SANA) aims to treat 40-60 patients in 2024 across multiple indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes. Early SC291 data shows safe dosing, immune evasion, and efficacy. Recent financing of $189.8 million supports operations. Q4 2023 cash position was $205.2 million with expected 2024 cash burn below $200 million.

Sana Biotechnology (SANA) to present at Cowen 44th Annual Health Care Conference on March 6, 2024, featuring a business overview by CEO Steve Harr.

Sana Biotechnology, Inc. achieves lasting glucose control in non-human primates with HIP-modified pancreatic islet cells, enabling insulin independence without immunosuppression. Anti-CD47 antibody demonstrates graft ablation safety strategy. The company aims to revolutionize type 1 diabetes treatment with potential clinical trials on the horizon.

Sana Biotechnology, Inc. successfully closed an underwritten upsized public offering, raising approximately $189.75 million by selling 21,772,728 shares of common stock and pre-funded warrants. The offering included the full exercise of the underwriters' option to purchase additional shares, with major investment banks acting as joint book-running managers.

Sana Biotechnology, Inc. (Nasdaq: SANA) has announced the pricing of its upsized public offering of 17,272,728 shares of common stock at $5.50 per share and pre-funded warrants to purchase 12,727,272 shares at $5.4999 per pre-funded warrant. The company has also granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares of its common stock. The gross proceeds from the offering are expected to be approximately $165.0 million before deducting underwriting discounts and commissions and other offering expenses.

Sana Biotechnology, Inc. has announced an underwritten public offering of $125.0 million of shares of its common stock, with the intention to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering. Morgan Stanley, J.P. Morgan, Goldman Sachs & Co. LLC, and BofA Securities are acting as joint book-running managers for the proposed offering. The proposed offering is being made pursuant to a Registration Statement on Form S-3, including a base prospectus, previously filed with and declared effective by the SEC.